Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence

The prophylactic use of myeloid growth factors reduces the risk of chemotherapy-induced neutropenia and its complications, including febrile neutropenia and infection-related mortality. Perhaps most importantly, the prophylactic use of colony-stimulating factors (CSFs) has been shown to reduce the need for chemotherapy dose reductions and delays that may limit chemotherapy dose intensity, thereby increasing the potential for prolonged disease-free and overall survival in the curative setting. National surveys have shown that the majority of patients with potentially curable breast cancer or non-Hodgkin's lymphoma (NHL) do not receive prophylactic CSF support. In this issue, the National Comprehensive Cancer Network presents guidelines for the use of myeloid growth factors in patients with cancer. These guidelines recommend a balanced clinical evaluation of the potential benefits and harms associated with chemotherapy to define the treatment intention, followed by a careful assessment of the individual patient's risk for febrile neutropenia and its complications. The decision to use prophylactic CSFs is then based on the patient's risk and potential benefit from such treatment. The routine prophylactic use of CSFs in patients receiving systemic chemotherapy is recommended in patients at high risk (>20%) of developing febrile neutropenia or related complications that may compromise treatment. Where compelling clinical indications are absent, the potential for CSF prophylaxis to reduce or offset costs by preventing hospitalization for FN should be considered. The clinical, economic, and quality of life data in support of these recommendations are reviewed, and important areas of ongoing research are highlighted.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Gary H. Lyman, MD, MPH, FRCP (Edin), University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Box 704, Rochester, NY 14642. E-mail: gary_lyman@urmc.rochester.edu
  • 1

    Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:112.

  • 2

    Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia. Potential effects on quality of life. Drugs 2002;62:6578.

  • 3

    Caggiano V, Weiss RV, Rickert TS. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:19161924.

    • Search Google Scholar
    • Export Citation
  • 4

    Lyman GH, Kuderer NM. The economics of the colony-stimulating factors for the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129146.

    • Search Google Scholar
    • Export Citation
  • 5

    Lyman GH, Morrison VA, Dale DCCJ. Risk of febrile neutropenia among patients with intermediate-grade Non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymph 2003;44:20692076.

    • Search Google Scholar
    • Export Citation
  • 6

    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228237.

    • Search Google Scholar
    • Export Citation
  • 7

    Dale DC, McCarter GC, Crawford J. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Cancer Network 2003;1:440454.

    • Search Google Scholar
    • Export Citation
  • 8

    Kuderer NM, Cosler L, Crawford J. Cost and mortality associated with febrile neutropenia in adult cancer patients (Abstr). Proc Am Soc Clin Oncol 2002;21:250a.

    • Search Google Scholar
    • Export Citation
  • 9

    Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:45244531.

    • Search Google Scholar
    • Export Citation
  • 10

    Griggs JT, Sorbero MES, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005;165:12671273.

  • 11

    Lyman GH, Dale DC, Friedberg J. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:43024311.

    • Search Google Scholar
    • Export Citation
  • 12

    Bonadonna G, Valagussa P, Moliterni A. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901906.

    • Search Google Scholar
    • Export Citation
  • 13

    Budman DR, Berry DA, Cirrincione CT. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:12051211.

    • Search Google Scholar
    • Export Citation
  • 14

    Kwak LW, Halpern J, Olshen RA. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963977.

    • Search Google Scholar
    • Export Citation
  • 15

    Epelbaum R, Faraggi D, Ben Arie Y. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990;66:11241129.

    • Search Google Scholar
    • Export Citation
  • 16

    Lepage E, Gisselbrecht C, Haioun C. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 1993;4:651656.

    • Search Google Scholar
    • Export Citation
  • 17

    Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164170.

    • Search Google Scholar
    • Export Citation
  • 18

    Trillet-Lenoir V, Green J, Manegold C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319324.

    • Search Google Scholar
    • Export Citation
  • 19

    Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406411.

    • Search Google Scholar
    • Export Citation
  • 20

    Ozer H, Armitage JO, Bennett CL. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:35583585.

    • Search Google Scholar
    • Export Citation
  • 21

    Holmes FA, O'Shaughnessy JA, Vukelja S. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk Stage II or Stage III/IV breast cancer. J Clin Oncol 2002;20:727731.

    • Search Google Scholar
    • Export Citation
  • 22

    Green MD, Koelbl H, Baselga J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:2935.

    • Search Google Scholar
    • Export Citation
  • 23

    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors in Cancer Treatment. Version 2.2005. Available at: www. nccn.org. Accessed June 2005.

    • Search Google Scholar
    • Export Citation
  • 24

    Bodey GP, Buckley M, Sathe YS. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328340.

    • Search Google Scholar
    • Export Citation
  • 25

    Meza L, Baselga J, Holmes FA. Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 2002;21:255b.

    • Search Google Scholar
    • Export Citation
  • 26

    Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOPR, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:24022409.

    • Search Google Scholar
    • Export Citation
  • 27

    Crawford J, Wolff D, Dale DC. First-cycle risk of severe and febrile neutropenia in cancer patient receiving systemic chemotherapy: results from a prospective nationwide study. Blood 2004;104:11.

    • Search Google Scholar
    • Export Citation
  • 28

    Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B: Routine use of granulocyte colony-stimulating factor is not cost-effective and does not incxrease patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998;16:27002707.

    • Search Google Scholar
    • Export Citation
  • 29

    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Fever and neutropenia, Version 1.2004. Available at http://www.nccn.org. Accessed June 2005.

    • Search Google Scholar
    • Export Citation
  • 30

    Kuderer NM, Dale D, Crawford J, Lyman GH. The impact of febrile neutropenia in hospitalized cancer patients: morbidity, mortality, and cost. J Clin Oncol 2004;22:14S.

    • Search Google Scholar
    • Export Citation
  • 31

    Lyman GH, Kuderer NM. Economics of hematopoietic growth factors. In: Morstyn G, Foote M, Lieschke GJ, eds. Cancer Drug Discovery and Development. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totowa, NJ: Humana Press Inc; 2004:409443.

    • Search Google Scholar
    • Export Citation
  • 32

    Cosler LE, Calhoun EA, Agboola O. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24:488494.

    • Search Google Scholar
    • Export Citation
  • 33

    Okon TA, Fortner BV, Schwartzberg L. Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN). Proc Am Soc Clin Oncol 2002;21:275b.

    • Search Google Scholar
    • Export Citation
  • 34

    Fortner BV, Stolshek BS, Tauer KW. Final analysis: Chemotherapy induced neutropenia (CIN) is associated with lower quality of life (QoL) in patients (pts) with cancer (Abstr #640P32). Ann Oncol 2002;13(Suppl 5):174.

    • Search Google Scholar
    • Export Citation
  • 35

    Padilla G, Ropka M: Quality of life and chemotherapy-induced neutropenia. Cancer Nurs. 2005;28:167-171.

  • 36

    Glaspy J, Hackett J, Flyer P. Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities. Blood 2001;98:432a.

    • Search Google Scholar
    • Export Citation
  • 37

    Nabhotz JM, Cantin J, Change J. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin.cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 2000;3:268275.

    • Search Google Scholar
    • Export Citation
  • 38

    Chu E, DeVita V: Principles of Medical Oncology. In: Cancer: Principles and Practice of Oncology, 7th ed.. Philadelphia: Lippincott, 2005, 295306.

    • Search Google Scholar
    • Export Citation
  • 39

    Skipper HE: Kinetics of Mannary Tumor Cell Growth and Implications for Therapy. Cancer 1971;28:1479.

  • 40

    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:16871717.

    • Search Google Scholar
    • Export Citation
  • 41

    Bonneterre J, Roche H, Kerbrat P. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French adjuvant study group 05 randomized trial. J Clin Oncol 2005;23:26862693.

    • Search Google Scholar
    • Export Citation
  • 42

    Ardizzoni A, Favaretto A, Boni L. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis—a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005;23:569575.

    • Search Google Scholar
    • Export Citation
  • 43

    Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 44

    Pfreundschuh M, Trümper L, Kloess M. 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634641.

    • Search Google Scholar
    • Export Citation
  • 45

    Osby E, Hagberg H, Kvaloy S. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:38403848.

    • Search Google Scholar
    • Export Citation
  • 46

    Doorduijn JK, van der HB, van Imhoff GW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:30413050.

    • Search Google Scholar
    • Export Citation
  • 47

    Timmer-Bonte J, Biesma J, Smit J. Prevention of chemotherapy-induced febrile neutropenia (FN) by antibiotics (AB) versus antibiotics plus granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC): a randomized phase III study. J Clin Oncol 2004;22:14S.

    • Search Google Scholar
    • Export Citation
  • 48

    Misset JL, Dieras V, Gruia G. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999;10:553560.

    • Search Google Scholar
    • Export Citation
  • 49

    Vogel CL, Wojtukiewicz MZ, Carroll RR. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:11781184.

    • Search Google Scholar
    • Export Citation
  • 50

    Bear HD, Anderson S, Brown A. The effect on tumor response of adding sequential preoperative docetaxel to pre-operative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:41654174.

    • Search Google Scholar
    • Export Citation
  • 51

    Chan S, Friedrichs K, Noel D. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:23412354.

    • Search Google Scholar
    • Export Citation
  • 52

    Kuderer NM, Crawford J, Dale DC, Lyman GH. Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy (Abstr #8117). J Clin Oncol 2005;23(16S):758s.

    • Search Google Scholar
    • Export Citation
  • 53

    Bohlius J, Reiser M, Schwarzer G. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004;CD003189.

    • Search Google Scholar
    • Export Citation
  • 54

    Sung L, Nathan PC, Lange B. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:33503356.

    • Search Google Scholar
    • Export Citation
  • 55

    Wittman B, Horan JT, Lyman GH. Prophylactic colony-stimulating factors in pediatric patients receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Blood 2004;104:11.

    • Search Google Scholar
    • Export Citation
  • 56

    Clark OA, Lyman G, Castro AA. Colony stimulating factors for chemotherapy induced febrile neutropenia. A meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198-4214.

    • Search Google Scholar
    • Export Citation
  • 57

    Pettengell R, Gurney H, Radford JA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:14301436.

    • Search Google Scholar
    • Export Citation
  • 58

    Zinzani PL, Pavone E, Storti S. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89:39743979.

    • Search Google Scholar
    • Export Citation
  • 59

    Pfreundshuh M, Trumper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 Trial of the DSHNHL. Blood 2004;104:626633.

    • Search Google Scholar
    • Export Citation
  • 60

    Glaspy JA, Bleeker G, Crawford J, Stoller R, Strauss M: The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A:2330.

    • Search Google Scholar
    • Export Citation
  • 61

    Lyman GH, Lyman CG, Sanderson RA. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488493.

    • Search Google Scholar
    • Export Citation
  • 62

    Lyman GH, Kuderer N, Greene J. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:18571864.

    • Search Google Scholar
    • Export Citation
  • 63

    Lyman GH, Kuderer NM: Cost effectiveness of myeloid growth factor in cancer chemotherapy. Curr Hemat Report 2003;2:471479.

  • 64

    Lyman GH, Kuderer NM: Economics of hematopoietic growth factors, In: Morstyn G, Foote M, Lieschke GJ, eds. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totowa, NJ: Humana Press Inc; 2004:409443.

    • Search Google Scholar
    • Export Citation
  • 65

    Cosler LE, Eldar Lissai A, Dale DC. Economic analysis of pegfilgrastim in patients receiving cancer chemotherapy. J Clin Oncol 2005;23(Suppl 16):538S.

    • Search Google Scholar
    • Export Citation
  • 66

    Lyman GH, Crawford J, Wolff D. A risk model for first cycle febrile neutropenia in cancer patients receiving systemic chemotherapy. J Clin Oncol 2005;23:759S.

    • Search Google Scholar
    • Export Citation
  • 67

    Cosler LE, Sivasubramaniam V, Agboola O. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value in Health 2005;8:4752.

    • Search Google Scholar
    • Export Citation
  • 68

    Silber JH, Fridman M, Shpilsky A. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998;16:24352544.

    • Search Google Scholar
    • Export Citation
  • 69

    Lyman GH: A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy 2000;20:104111.

  • 70

    Lyman GH: Risk assessment in oncology clinical practice: from risk factors to risk models (Lyman GH, ed). Oncology 2003;17:813.

  • 71

    Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-437.

  • 72

    Mackey JR, Paterson A, Dirix LY. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21:35a.

    • Search Google Scholar
    • Export Citation
  • 73

    Nabholtz J, Pienkowski T, Mackey J. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclosphosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21:36a

    • Search Google Scholar
    • Export Citation
  • 74

    Intragumtornchai T, Sutheesophon J, Sutcharitchan P. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000;37:351360.

    • Search Google Scholar
    • Export Citation
  • 75

    Klastersky J, Paesmans M, Rubenstein EB. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:30383051.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 5 0 0
Full Text Views 232 155 14
PDF Downloads 130 107 9
EPUB Downloads 0 0 0